Page last updated: 2024-11-05

5-tolyltriazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-tolyltriazole: a corrosion inhibitor and water pollutant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8705
CHEMBL ID2148100
CHEBI ID83455
SCHEMBL ID103309
MeSH IDM000601840

Synonyms (64)

Synonym
nsc-122012
6-methyl-1,3-benzotriazole
5-methyl-1,3-benzotriazole
136-85-6
wln: t56 bmnnj g1
nsc122012
5-methylbenzotriazole
AC-16224
6-methyl-1h-benzotriazole
BB 0243855
nsc 122012
einecs 205-265-8
6-methylbenzotriazole
6-methyl-1,2,3-benzotriazole
ccris 6780
5-methyl-1,2,3-benzotriazole
brn 0116658
tolutriazole
1h-benzotriazole, 5-methyl-
5-methyl-1h-benzotriazole, 98%
5-methyl-1h-benzotriazole ,
5-methyl-2h-benzotriazole
AKOS005061650
M0249
AKOS003234056
o9di72tu6u ,
unii-o9di72tu6u
1h-benzotriazole, 6-methyl-
5-tolyltriazole
4-26-00-00144 (beilstein handbook reference)
CHEMBL2148100
chebi:83455 ,
5-methyl-1h-benzo[d][1,2,3]triazole
FT-0620587
SCHEMBL103309
retrocure g (salt/mix)
5-methyl-1h-1,2,3-benzotriazole #
vulkalent tm (salt/mix)
5-methyl-1h-benzo-1,2,3-triazole
dtxcid9018743
NCGC00356952-01
cas-136-85-6
tox21_303925
dtxsid1038743 ,
benzotriazole, 5-methyl-
verzone vt 120m
5-methyl-1h-benzo(d)(1,2,3)triazole
methyl-1h-benzotriazole. 5-
6-tolyltriazole
W-109487
mfcd00005702
5-methyl-1h-benzotriazole, analytical standard
5me-bt
5-me-bt
5mebt
5-me-btr
SY036766
5-methyl-1h-benzotriazole, pract.
AS-12986
Q17493530
H11245
6(or7)-methyl-1h-benzo[d][1,2,3]triazole
CS-0127964
5-methyl-1h-benzo[d][1,2,3]triazole(chunks or pellets)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzotriazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency27.53573.189029.884159.4836AID1224846
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.27710.001022.650876.6163AID1224838
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID687183Inhibition of human recombinant N-terminal His-tagged IDO1 (Ala2 to Gly403) overexpressed in Escherichia coli BL21 at 1 mM at pH 6.5 after 60 mins by HPLC analysis2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's10 (83.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.39 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.77 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]